{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Anti-cancerous", "Cancer.", "Clinical trials", "Medicinal plants", "Phytochemicals", "Pre-clinical trials"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38279745", "DateCompleted": {"Year": "2024", "Month": "07", "Day": "15"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "15"}, "Article": {"Language": ["eng"], "ELocationID": ["10.2174/0115680266282518231231075311"], "ArticleDate": [], "Journal": {"ISSN": "1873-4294", "JournalIssue": {"Volume": "24", "Issue": "12", "PubDate": {"Year": "2024"}}, "Title": "Current topics in medicinal chemistry", "ISOAbbreviation": "Curr Top Med Chem"}, "ArticleTitle": "Phytotherapeutics in Cancer: From Potential Drug Candidates to Clinical Translation.", "Pagination": {"StartPage": "1050", "EndPage": "1074", "MedlinePgn": "1050-1074"}, "Abstract": {"AbstractText": ["Annually, a significant number of individuals succumb to cancer, an anomalous cellular condition characterized by uncontrolled cellular proliferation and the emergence of highly perilous tumors. Identifying underlying molecular mechanism(s) driving disease progression has led to various inventive therapeutic approaches, many of which are presently under pre-clinical and/or clinical trials. Over the recent years, numerous alternative strategies for addressing cancer have also been proposed and put into practice. This article delineates the modern therapeutic drugs employed in cancer treatment and their associated toxicity. Due to inherent drug toxicity associated with most modern treatments, demand rises for alternative therapies and phytochemicals with minimal side effects and proven efficacy against cancer. Analogs of taxol, <i>Vinca</i> alkaloids like vincristine and vinblastine, and podophyllotoxin represent a few illustrative examples in this context. The phytochemicals often work by modifying the activity of molecular pathways that are thought to be involved in the onset and progression of cancer. The principal objective of this study is to provide an overview of our current understanding regarding the pharmacologic effects and molecular targets of the active compounds found in natural products for cancer treatment and collate information about the recent advancements in this realm. The authors' interest in advancing the field of phytochemical research stems from both the potential of these compounds for use as drugs as well as their scientific validity. Accordingly, the significance of herbal formulations is underscored, shedding light on anticancer phytochemicals that are sought after at both pre-clinical and clinical levels, with discussion on the opportunities and challenges in pre-clinical and clinical cancer studies."], "CopyrightInformation": "Copyright\u00a9 Bentham Science Publishers; For any queries, please email at epub@benthamscience.net."}, "AuthorList": [{"Identifier": ["0000-0003-0393-8857"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad, 201206, India."}], "LastName": "Grover", "ForeName": "Parul", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Zoology, University of Delhi, Delhi, 110007, India."}], "LastName": "Thakur", "ForeName": "Kulbhushan", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Product and Medicinal Chemistry Division, Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu, 180001, India."}], "LastName": "Bhardwaj", "ForeName": "Monika", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Amity Institute of Pharmacy, Amity University, Noida, 201301, India."}], "LastName": "Mehta", "ForeName": "Lovekesh", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, Noida, 201301, India."}], "LastName": "Raina", "ForeName": "Soom Nath", "Initials": "SN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Botany, Hansraj College, Delhi University, Delhi, 110007, India."}], "LastName": "Rajpal", "ForeName": "Vijay Rani", "Initials": "VR"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "United Arab Emirates", "MedlineTA": "Curr Top Med Chem", "NlmUniqueID": "101119673", "ISSNLinking": "1568-0266"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents, Phytogenic"}, {"RegistryNumber": "0", "NameOfSubstance": "Phytochemicals"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Neoplasms"}, {"QualifierName": ["pharmacology", "chemistry"], "DescriptorName": "Antineoplastic Agents, Phytogenic"}, {"QualifierName": ["pharmacology", "chemistry"], "DescriptorName": "Phytochemicals"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Rahman M.A.; Hannan M.A.; Dash R.; Rahman M.D.H.; Islam R.; Uddin M.J.; Sohag A.A.M.; Rahman M.H.; Rhim H.; Phytochemicals as a complement to cancer chemotherapy: Pharmacological modulation of the autophagy-apoptosis pathway. Front Pharmacol 2021,12,639628", "ArticleIdList": ["10.3389/fphar.2021.639628", "34025409"]}, {"Citation": "Bhatia K.; Bhumika ; Das A.; Combinatorial drug therapy in cancer: New insights. Life Sci 2020,258,118134", "ArticleIdList": ["10.1016/j.lfs.2020.118134", "32717272"]}, {"Citation": "Sanford N.N.; Sher D.J.; Xu X.; Ahn C.; D\u2019Amico A.V.; Aizer A.A.; Mahal B.A.; Alcohol use among patients with cancer and survivors in the United States, 2000\u20132017. J Natl Compr Canc Netw 2020,18(1),69-79", "ArticleIdList": ["10.6004/jnccn.2019.7341", "31910381"]}, {"Citation": "Khaltaev N.; Axelrod S.; Global lung cancer mortality trends and lifestyle modifications: Peliminary analysis. Chin Med J 2020,133(13),1526-1532", "ArticleIdList": ["10.1097/CM9.0000000000000918", "32568874"]}, {"Citation": "Hartwig A.; Arand M.; Epe B.; Guth S.; Jahnke G.; Lampen A.; Martus H.J.; Monien B.; Rietjens I.M.C.M.; Schmitz-Spanke S.; Schriever-Schwemmer G.; Steinberg P.; Eisenbrand G.; Mode of action-based risk assessment of genotoxic carcinogens. Arch Toxicol 2020,94(6),1787-1877", "ArticleIdList": ["10.1007/s00204-020-02733-2", "32542409"]}, {"Citation": "Hanna T.P.; King W.D.; Thibodeau S.; Jalink M.; Paulin G.A.; Harvey-Jones E.; O\u2019Sullivan D.E.; Booth C.M.; Sullivan R.; Aggarwal A.; Mortality due to cancer treatment delay: Systematic review and meta-analysis. bmj 2020,371"}, {"Citation": "Henley S.J.; Ward E.M.; Scott S.; Ma J.; Anderson R.N.; Firth A.U.; Thomas C.C.; Islami F.; Weir H.K.; Lewis D.R.; Sherman R.L.; Wu M.; Benard V.B.; Richardson L.C.; Jemal A.; Cronin K.; Kohler B.A.; Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer 2020,126(10),2225-2249", "ArticleIdList": ["10.1002/cncr.32802", "32162336"]}, {"Citation": "Markham M.J.; Wachter K.; Agarwal N.; Bertagnolli M.M.; Chang S.M.; Dale W.; Diefenbach C.S.M.; Rodriguez-Galindo C.; George D.J.; Gilligan T.D.; Harvey R.D.; Johnson M.L.; Kimple R.J.; Knoll M.A.; LoConte N.; Maki R.G.; Meisel J.L.; Meyerhardt J.A.; Pennell N.A.; Rocque G.B.; Sabel M.S.; Schilsky R.L.; Schneider B.J.; Tap W.D.; Uzzo R.G.; Westin S.N.; Clinical cancer advances 2020: Annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol 2020,38(10),1081", "ArticleIdList": ["10.1200/JCO.19.03141", "32013670"]}, {"Citation": "Schirrmacher V.; From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol 2018,54(2),407-419", "ArticleIdList": ["10.3892/ijo.2018.4661", "30570109"]}, {"Citation": "Sak K.; Site-specific anticancer effects of dietary flavonoid quercetin. Nutr Cancer 2014,66(2),177-193", "ArticleIdList": ["10.1080/01635581.2014.864418", "24377461"]}, {"Citation": "Alfarouk K.O.; Stock C.M.; Taylor S.; Walsh M.; Muddathir A.K.; Verduzco D.; Bashir A.H.H.; Mohammed O.Y.; Elhassan G.O.; Harguindey S.; Reshkin S.J.; Ibrahim M.E.; Rauch C.; Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp. Cancer Cell Int 2015,15(1),71", "ArticleIdList": ["10.1186/s12935-015-0221-1", "26180516"]}, {"Citation": "Wang X.; Zhang H.; Chen X.; Drug resistance and combating drug resistance in cancer. Cancer Drug Resist 2019,2(2),141-160", "ArticleIdList": ["10.20517/cdr.2019.10", "34322663"]}, {"Citation": "Grover P.; Bhardwaj M.; Mehta L.; Kapoor G.; Chawla P.A.; Current developments in the pyran-based analogues as anticancer agents. Anticancer Agents Med Chem 2022,22(19),3239-3268", "ArticleIdList": ["10.2174/1871520621666211119090302", "34802409"]}, {"Citation": "Aung T.; Qu Z.; Kortschak R.; Adelson D.; Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action. Int J Mol Sci 2017,18(3),656", "ArticleIdList": ["10.3390/ijms18030656", "28304343"]}, {"Citation": "Choudhari A.S.; Mandave P.C.; Deshpande M.; Ranjekar P.; Prakash O.; Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Front Pharmacol 2020,10,1614", "ArticleIdList": ["10.3389/fphar.2019.01614", "32116665"]}, {"Citation": "George B.P.; Chandran R.; Abrahamse H.; Role of phytochemicals in cancer chemoprevention: Insights. Antioxidants 2021,10(9),1455", "ArticleIdList": ["10.3390/antiox10091455", "34573087"]}, {"Citation": "Ahmed M.B.; Islam S.U.; Alghamdi A.A.A.; Kamran M.; Ahsan H.; Lee Y.S.; Phytochemicals as chemo-preventive agents and signaling molecule modulators: Current role in cancer therapeutics and inflammation. Int J Mol Sci 2022,23(24),15765", "ArticleIdList": ["10.3390/ijms232415765", "36555406"]}, {"Citation": "Anand U.; Dey A.; Chandel A.K.S.; Sanyal R.; Mishra A.; Pandey D.K.; De Falco V.; Upadhyay A.; Kandimalla R.; Chaudhary A.; Dhanjal J.K.; Dewanjee S.; Vallamkondu J.; P\u00e9rez de la Lastra J.M.; Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 2023,10(4),1367-1401", "ArticleIdList": ["10.1016/j.gendis.2022.02.007", "37397557"]}, {"Citation": "J\u00e4ger U.; Barcellini W.; Broome C.M.; Gertz M.A.; Hill A.; Hill Q.A.; Jilma B.; Kuter D.J.; Michel M.; Montillo M.; R\u00f6th A.; Zeerleder S.S.; Berentsen S.; Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the first international consensus meeting. Blood Rev 2020,41,100648", "ArticleIdList": ["10.1016/j.blre.2019.100648", "31839434"]}, {"Citation": "Begna K.; Abdelatif A.; Schwager S.; Hanson C.; Pardanani A.; Tefferi A.; Busulfan for the treatment of myeloproliferative neoplasms: The mayo clinic experience. Blood Cancer J 2016,6(5),e427", "ArticleIdList": ["10.1038/bcj.2016.34", "27232929"]}, {"Citation": "Ho G.Y.; Woodward N.; Coward J.I.G.; Cisplatin versus carboplatin: Comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 2016,102,37-46", "ArticleIdList": ["10.1016/j.critrevonc.2016.03.014", "27105947"]}, {"Citation": "Yerram P.; Reiss S.N.; Modelevsky L.; Gavrilovic I.T.; Kaley T.; Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas. J Neurooncol 2019,145(1),57-63", "ArticleIdList": ["10.1007/s11060-019-03266-0", "31432377"]}, {"Citation": "Lee H.Z.; Miller B.W.; Kwitkowski V.E.; Ricci S.; DelValle P.; Saber H.; Grillo J.; Bullock J.; Florian J.; Mehrotra N.; Ko C.W.; Nie L.; Shapiro M.; Tolnay M.; Kane R.C.; Kaminskas E.; Justice R.; Farrell A.T.; Pazdur R.; U.S. Food and drug administration approval: Obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. Clin Cancer Res 2014,20(15),3902-3907", "ArticleIdList": ["10.1158/1078-0432.CCR-14-0516", "24824310"]}, {"Citation": "Raudenska M.; Balvan J.; Fojtu M.; Gumulec J.; Masarik M.; Unexpected therapeutic effects of cisplatin. Metallomics 2019,11(7),1182-1199", "ArticleIdList": ["10.1039/c9mt00049f", "31098602"]}, {"Citation": "Casak S.J.; Lemery S.J.; Shen Y.L.; Rothmann M.D.; Khandelwal A.; Zhao H.; Davis G.; Jarral V.; Keegan P.; Pazdur R.; U.S. Food and drug administration approval: Rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. Oncologist 2011,16(1),97-104", "ArticleIdList": ["10.1634/theoncologist.2010-0306", "21212432"]}, {"Citation": "Velho T.; Metastatic melanoma :A review of current and future drugs. Drugs Context 2012,2012,1-17", "ArticleIdList": ["10.7573/dic.212242", "24432031"]}, {"Citation": "Grover P.; Bhardwaj M.; Kapoor G.; Mehta L.; Ghai R.; Nagarajan K.; Advances on quinazoline based congeners for anticancer potential. Curr Org Chem 2021,25(6),695-723", "ArticleIdList": ["10.2174/1385272825666210212121056"]}, {"Citation": "Dhillon S.; Decitabine/cedazuridine: First approval. Drugs 2020,80(13),1373-1378", "ArticleIdList": ["10.1007/s40265-020-01389-7", "32860582"]}, {"Citation": "Cagel M.; Grotz E.; Bernabeu E.; Moretton M.A.; Chiappetta D.A.; Doxorubicin: Nanotechnological overviews from bench to bedside. Drug Discov Today 2017,22(2),270-281", "ArticleIdList": ["10.1016/j.drudis.2016.11.005", "27890669"]}, {"Citation": "Buzdar A.U.; Suman V.J.; Meric-Bernstam F.; Leitch A.M.; Ellis M.J.; Boughey J.C.; Unzeitig G.; Royce M.; McCall L.M.; Ewer M.S.; Hunt K.K.; Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): A randomised, controlled, phase 3 trial. Lancet Oncol 2013,14(13),1317-1325", "ArticleIdList": ["10.1016/S1470-2045(13)70502-3", "24239210"]}, {"Citation": "Hande K.R.; Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998,34(10),1514-1521", "ArticleIdList": ["10.1016/S0959-8049(98)00228-7", "9893622"]}, {"Citation": "Faulds D.; Balfour J.A.; Chrisp P.; Langtry H.D.; Mitoxantrone. Drugs 1991,41(3),400-449", "ArticleIdList": ["10.2165/00003495-199141030-00007", "1711446"]}, {"Citation": "Matz E.L.; Hsieh M.H.; Review of advances in uroprotective agents for cyclophosphamide-and ifosfamide-induced hemorrhagic cystitis. Urology 2017,100,16-19", "ArticleIdList": ["10.1016/j.urology.2016.07.030", "27566144"]}, {"Citation": "de Man F.M.; Goey A.K.L.; van Schaik R.H.N.; Mathijssen R.H.J.; Bins S.; Individualization of irinotecan treatment: A review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet 2018,57(10),1229-1254", "ArticleIdList": ["10.1007/s40262-018-0644-7", "29520731"]}, {"Citation": "KuKanich B.; Warner M.; Hahn K.; Analysis of lomustine drug content in FDA-approved and compounded lomustine capsules. J Am Vet Med Assoc 2017,250(3),322-326", "ArticleIdList": ["10.2460/javma.250.3.322", "28117638"]}, {"Citation": "Chen Y.; Jia Y.; Song W.; Zhang L.; Therapeutic potential of nitrogen mustard based hybrid molecules. Front Pharmacol 2018,9,1453", "ArticleIdList": ["10.3389/fphar.2018.01453", "30618747"]}, {"Citation": "Sun J.; Wei Q.; Zhou Y.; Wang J.; Liu Q.; Xu H.; A systematic analysis of FDA-approved anticancer drugs. BMC Syst Biol 2017,11(S5)(Suppl. 5),87", "ArticleIdList": ["10.1186/s12918-017-0464-7", "28984210"]}, {"Citation": "Crooke S.T.; Bradner W.T.; Mitomycin C: A review. Cancer Treat Rev 1976,3(3),121-139", "ArticleIdList": ["10.1016/S0305-7372(76)80019-9", "786455"]}, {"Citation": "Fox E.J.; Mechanism of action of mitoxantrone. Neurology 2004,63(12)(Suppl. 6),S15-S18", "ArticleIdList": ["15623664"]}, {"Citation": "Stein A.; Arnold D.; Oxaliplatin: A review of approved uses. Expert Opin Pharmacother 2012,13(1),125-137", "ArticleIdList": ["10.1517/14656566.2012.643870", "22149372"]}, {"Citation": "Mutter N.; Stupp R.; Temozolomide: A milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 2006,6(8),1187-1204", "ArticleIdList": ["10.1586/14737140.6.8.1187", "16925485"]}, {"Citation": "Garst J.; Topotecan: An evolving option in the treatment of relapsed small cell lung cancer. Ther Clin Risk Manag 2007,3(6),1087-1095", "ArticleIdList": ["18516270"]}, {"Citation": "Kokolo M.B.; Fergusson D.; O\u2019Neill J.; Tay J.; Tinmouth A.T.; Stewart D.; Bredeson C.; Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma. Leuk Lymphoma 2014,55(12),2712-2720", "ArticleIdList": ["10.3109/10428194.2014.889825", "24491026"]}, {"Citation": "D\u2019Incalci M.; Badri N.; Galmarini C.M.; Allavena P.; Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer 2014,111(4),646-650", "ArticleIdList": ["10.1038/bjc.2014.149", "24755886"]}, {"Citation": "Broen J.C.A.; van Laar J.M.; Mycophenolate mofetil, azathioprine and tacrolimus: Mechanisms in rheumatology. Nat Rev Rheumatol 2020,16(3),167-178", "ArticleIdList": ["10.1038/s41584-020-0374-8", "32055040"]}, {"Citation": "Rosenberg J.D.; Burian C.; Waalen J.; Saven A.; Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: A single-institution series. Blood 2014,123(2),177-183", "ArticleIdList": ["10.1182/blood-2013-06-508754", "24192579"]}, {"Citation": "Zhenchuk A.; Lotfi K.; Juliusson G.; Albertioni F.; Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol 2009,78(11),1351-1359", "ArticleIdList": ["10.1016/j.bcp.2009.06.094", "19576186"]}, {"Citation": "Ricci F.; Tedeschi A.; Morra E.; Montillo M.; Fludarabine in the treatment of chronic lymphocytic leukemia: A review. Ther Clin Risk Manag 2009,5(1),187-207", "ArticleIdList": ["19436622"]}, {"Citation": "Mini E.; Nobili S.; Caciagli B.; Landini I.; Mazzei T.; Cellular pharmacology of gemcitabine. Ann Oncol 2006,17(Suppl. 5),v7-v12", "ArticleIdList": ["10.1093/annonc/mdj941", "16807468"]}, {"Citation": "Fan P.O.L.; Leung K.T.; Chan K.Y.Y.; Leung A.W.K.; Lam G.K.S.; Chow T.T.W.; Cheng F.W.T.; Yuen L.Y.P.; Moriyama T.; Yang J.J.; Li C.K.; ABCC4, ITPA, NUDT15, TPMT and their interaction as genetic predictors of 6-mercaptopurine intolerance in chinese patients with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2022,39(3),254-266", "ArticleIdList": ["10.1080/08880018.2021.1973628", "34665987"]}, {"Citation": "Amer-Salas N.; Gonz\u00e1lez-Morcillo G.; Rodr\u00edguez-Camacho J.M.; Cladera-Serra A.; Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report. J Oncol Pharm Pract 2021,27(1),244-249", "ArticleIdList": ["10.1177/1078155220929747", "32517638"]}, {"Citation": "Kempin S.; Sun Z.; Kay N.E.; Paietta E.M.; Mazza J.J.; Ketterling R.P.; Frankfurt O.; Claxton D.F.; Saltzman J.N.; Srkalovic G.; Callander N.S.; Gross G.; Tallman M.S.; Pentostatin, cyclophosphamide, and rituximab followed by alemtuzumab for relapsed or refractory chronic lymphocytic leukemia: A phase 2 trial of the ECOG-Acrin Cancer Research Group (E2903). Acta Haematol 2019,142(4),224-232", "ArticleIdList": ["10.1159/000500164", "31336367"]}, {"Citation": "Florin T.H.; Duley J.A.; Therapeutic drug monitoring for IBD children on thioguanine. J Pediatr Gastroenterol Nutr 2023,77(3),e64-e65", "ArticleIdList": ["10.1097/MPG.0000000000003870", "37346029"]}, {"Citation": "Yang B.; Xie X.; Lv D.; Hu J.; Chen Y.; Wu Z.; Luo S.; Zhang S.; Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil. Br J Cancer 2023,128(2),219-231", "ArticleIdList": ["10.1038/s41416-022-02039-3", "36347964"]}, {"Citation": "Consoli G.M.L.; Giuffrida M.L.; Zimbone S.; Ferreri L.; Maugeri L.; Palmieri M.; Satriano C.; Forte G.; Petralia S.; Green light-triggerable chemo-photothermal activity of cytarabine-loaded polymer carbon dots: mechanism and preliminary in vitro evaluation. ACS Appl Mater Interfaces 2023,15(4),5732-5743", "ArticleIdList": ["10.1021/acsami.2c22500", "36688816"]}, {"Citation": "Zhang Y.; Chen L.; Hu G.Q.; Zhang N.; Zhu X.D.; Yang K.Y.; Jin F.; Shi M.; Chen Y.P.; Hu W.H.; Cheng Z.B.; Wang S.Y.; Tian Y.; Wang X.C.; Sun Y.; Li J.G.; Li W.F.; Li Y.H.; Tang L.L.; Mao Y.P.; Zhou G.Q.; Sun R.; Liu X.; Guo R.; Long G.X.; Liang S.Q.; Li L.; Huang J.; Long J.H.; Zang J.; Liu Q.D.; Zou L.; Su Q.F.; Zheng B.M.; Xiao Y.; Guo Y.; Han F.; Mo H.Y.; Lv J.W.; Du X.J.; Xu C.; Liu N.; Li Y.Q.; Chua M.L.K.; Xie F.Y.; Sun Y.; Ma J.; Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019,381(12),1124-1135", "ArticleIdList": ["10.1056/NEJMoa1905287", "31150573"]}, {"Citation": "De Luca O.; Salerno G.; De Bernardini D.; Torre M.S.; Simmaco M.; Lionetto L.; Gentile G.; Borro M.; Predicting dihydropyrimidine dehydrogenase deficiency and related 5-fluorouracil toxicity: Opportunities and challenges of DPYD exon sequencing and the role of phenotyping assays. Int J Mol Sci 2022,23(22),13923", "ArticleIdList": ["10.3390/ijms232213923", "36430399"]}, {"Citation": "Bi Y.; Wang Y.; Zhang W.; Lu H.; Ren J.; Han X.; Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma. Cancer Imaging 2023,23(1),19", "ArticleIdList": ["10.1186/s40644-023-00534-1", "36814327"]}, {"Citation": "Zhang S.C.; Yu M.Y.; Xi L.; Zhang J.X.; Tegafur deteriorates established cardiovascular atherosclerosis in colon cancer: A case report and review of the literature. World J Clin Cases 2019,7(1),89-94", "ArticleIdList": ["10.12998/wjcc.v7.i1.89", "30637257"]}, {"Citation": "Gesundheit B.; Shapira M.Y.; Resnick I.; Bitan M.; Ben-Yehuda D.; Slavin S.; Or R.; Trisenox (Arsenic Trioxide) in the treatment for multiple myeloma after bone marrow transplantation. Blood 2005,106(11),5128", "ArticleIdList": ["10.1182/blood.V106.11.5128.5128"]}, {"Citation": "Tshilolo L.; Tomlinson G.; Williams T.N.; Santos B.; Olupot-Olupot P.; Lane A.; Aygun B.; Stuber S.E.; Latham T.S.; McGann P.T.; Ware R.E.; Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. N Engl J Med 2019,380(2),121-131", "ArticleIdList": ["10.1056/NEJMoa1813598", "30501550"]}, {"Citation": "Kuriakose G.C.; Arathi B.P.; Divya Lakshmanan M.; Jiby M.V.; Gudde R.S.; Jayabhaskaran C.; Sub-acute toxicity assessment of taxol isolated from Fusarium solani, an endophytic fungus of Taxus brevifolia, in wistar rats and analyzing its cytotoxicity and apoptotic potential in lung cancer cells. Front Oncol 2020,10,538865", "ArticleIdList": ["10.3389/fonc.2020.538865", "33117679"]}, {"Citation": "Bee H.; Ixempra and neuropathy. Sign 2018,5,35"}, {"Citation": "Ranganathan P.; Monitoring methotrexate toxicity: Are we being over-vigilant. bmj 2023,30,381"}, {"Citation": "Vogelzang N.J.; Rusthoven J.J.; Symanowski J.; Denham C.; Kaukel E.; Ruffie P.; Gatzemeier U.; Boyer M.; Emri S.; Manegold C.; Niyikiza C.; Paoletti P.; Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2023,41(12),2125-2133", "ArticleIdList": ["10.1200/JCO.22.02542", "37068377"]}, {"Citation": "Rayan A.; Raiyn J.; Falah M.; Nature is the best source of anticancer drugs: Indexing natural products for their anticancer bioactivity. PLoS One 2017,12(11),e0187925", "ArticleIdList": ["10.1371/journal.pone.0187925", "29121120"]}, {"Citation": "da Costa R.; Passos G.F.; Quint\u00e3o N.L.M.; Fernandes E.S.; Maia J.R.L.C.B.; Campos M.M.; Calixto J.B.; Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives. Br J Pharmacol 2020,177(14),3127-3146", "ArticleIdList": ["10.1111/bph.15086", "32352155"]}, {"Citation": "Arora R.D.; Menezes R.G.; Vinca Alkaloid Toxicity. In: StatPearls 2023"}, {"Citation": "Wu J.; Liu Z.; Progress in the management of acute colchicine poisoning in adults. Intern Emerg Med 2022,17(7),2069-2081", "ArticleIdList": ["10.1007/s11739-022-03079-6", "36028733"]}, {"Citation": "Saxena M.; Saxena J.; Nema R.; Singh D.; Gupta A.; Phytochemistry of medicinal plants. J Pharmacogn Phytochem 2013,1,168-182"}, {"Citation": "Saklani A.; Kutty S.; Plant-derived compounds in clinical trials. Drug Discov Today 2008,13(3-4),161-171", "ArticleIdList": ["10.1016/j.drudis.2007.10.010", "18275914"]}, {"Citation": "Elrayess R.A.; Gad El-Hak H.N.; Anticancer natural products: A Review. Cancer Stud Mol Med 2019,5(1),11-22", "ArticleIdList": ["10.17140/CSMMOJ-5-127"]}, {"Citation": "Palmirotta R.; Lovero D.; Cafforio P.; Felici C.; Mannavola F.; Pell\u00e8 E.; Quaresmini D.; Tucci M.; Silvestris F.; Liquid biopsy of cancer: A multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol 2018,10", "ArticleIdList": ["10.1177/1758835918794630", "30181785"]}, {"Citation": "Kutova O.; Guryev E.; Sokolova E.; Alzeibak R.; Balalaeva I.; Targeted delivery to tumors: Multidirectional strategies to improve treatment efficiency. Cancers 2019,11(1),68", "ArticleIdList": ["10.3390/cancers11010068", "30634580"]}, {"Citation": "Yadav R.; Das P.P.; Sharma S.; Sengupta S.; Kumar D.; Sagar R.; Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment. Med Oncol 2023,40(12),347", "ArticleIdList": ["10.1007/s12032-023-02195-3", "37930458"]}, {"Citation": "Younis N.K.; Roumieh R.; Bassil E.P.; Ghoubaira J.A.; Kobeissy F.; Eid A.H.; Nanoparticles: Attractive tools to treat colorectal cancer. In Seminars in Cancer Biology 2022"}, {"Citation": "Feng Y.; Cao Y.; Singh R.; Janjua T.I.; Popat A.; Silica nanoparticles for brain cancer. Exp Opin Drug Del 2023"}, {"Citation": "Sun L.; Liu H.; Ye Y.; Lei Y.; Islam R.; Tan S.; Tong R.; Miao Y.B.; Cai L.; Smart nanoparticles for cancer therapy. Signal Transduct Target Ther 2023,8(1),418", "ArticleIdList": ["10.1038/s41392-023-01642-x", "37919282"]}, {"Citation": "Singh S.; Sachan K.; Verma S.; Singh N.; Singh P.K.; Cubosomes: An emerging and promising drug delivery system for enhancing cancer therapy. Curr Pharm Biotechnol 2024", "ArticleIdList": ["37929730"]}, {"Citation": "Rosenblum D.; Joshi N.; Tao W.; Karp J.M.; Peer D.; Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun 2018,9(1),1410", "ArticleIdList": ["10.1038/s41467-018-03705-y", "29650952"]}, {"Citation": "Zaman A.; Wu W.; Bivona T.G.; Targeting oncogenic BRAF: Past, present, and future. Cancers 2019,11(8),1197", "ArticleIdList": ["10.3390/cancers11081197", "31426419"]}, {"Citation": "Andr\u00e9 F.; Ciruelos E.; Rubovszky G.; Campone M.; Loibl S.; Rugo H.S.; Iwata H.; Conte P.; Mayer I.A.; Kaufman B.; Yamashita T.; Lu Y.S.; Inoue K.; Takahashi M.; P\u00e1pai Z.; Longin A.S.; Mills D.; Wilke C.; Hirawat S.; Juric D.; Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019,380(20),1929-1940", "ArticleIdList": ["10.1056/NEJMoa1813904", "31091374"]}, {"Citation": "Kalra R.S.; Bapat S.A.; Springer; New York: Proteomics to predict loss of RXR-\u03b3 during progression of epithelial ovarian cancer. Methods Mol Biol 2019,1-14", "ArticleIdList": ["31359385"]}, {"Citation": "de la Fuente-N\u00fa\u00f1ez C.; Silva O.N.; Lu T.K.; Franco O.L.; Antimicrobial peptides: Role in human disease and potential as immunotherapies. Pharmacol Ther 2017,178,132-140", "ArticleIdList": ["10.1016/j.pharmthera.2017.04.002", "28435091"]}, {"Citation": "Fel\u00edcio M.R.; Silva O.N.; Gon\u00e7alves S.; Santos N.C.; Franco O.L.; Peptides with dual antimicrobial and anticancer activities. Front Chem 2017,5,5", "ArticleIdList": ["10.3389/fchem.2017.00005", "28271058"]}, {"Citation": "Hilchie A.L.; Hoskin D.W.; Power Coombs M.R.; Power Coombs M.R. Anticancer activities of natural and synthetic peptides. Adv Exp Med Biol 2019,1117,131-147", "ArticleIdList": ["10.1007/978-981-13-3588-4_9", "30980357"]}, {"Citation": "Mwangi J.; Hao X.; Lai R.; Zhang Z.Y.; Antimicrobial peptides: New hope in the war against multidrug resistance. Zool Res 2019,40(6),488-505", "ArticleIdList": ["10.24272/j.issn.2095-8137.2019.062", "31592585"]}, {"Citation": "Qin Y.; Qin Z.D.; Chen J.; Cai C.G.; Li L.; Feng L.Y.; Wang Z.; Duns G.J.; He N.Y.; Chen Z.S.; Luo X.F.; From antimicrobial to anticancer peptides: The transformation of peptides. Recent Patents Anticancer Drug Discov 2019,14(1),70-84", "ArticleIdList": ["10.2174/1574892814666190119165157", "30663573"]}, {"Citation": "Lei J.; Sun L.; Huang S.; Zhu C.; Li P.; He J.; Mackey V.; Coy D.H.; He Q.; The antimicrobial peptides and their potential clinical applications. Am J Transl Res 2019,11(7),3919-3931", "ArticleIdList": ["31396309"]}, {"Citation": "Roudi R.; Syn N.L.; Roudbary M.; Antimicrobial peptides as biologic and immunotherapeutic agents against cancer: A comprehensive overview. Front Immunol 2017,8,1320", "ArticleIdList": ["10.3389/fimmu.2017.01320", "29081781"]}, {"Citation": "Tornesello A.L.; Borrelli A.; Buonaguro L.; Buonaguro F.M.; Tornesello M.L.; Antimicrobial peptides as anticancer agents: Functional properties and biological activities. Molecules 2020,25(12),2850", "ArticleIdList": ["10.3390/molecules25122850", "32575664"]}, {"Citation": "Khare T.; Anand U.; Dey A.; Assaraf Y.G.; Chen Z.S.; Liu Z.; Kumar V.; Exploring phytochemicals for combating antibiotic resistance in microbial pathogens. Front Pharmacol 2021,12,720726", "ArticleIdList": ["10.3389/fphar.2021.720726", "34366872"]}, {"Citation": "van Harten R.; van Woudenbergh E.; van Dijk A.; Haagsman H.; Cathelicidins: Immunomodulatory antimicrobials. Vaccines 2018,6(3),63", "ArticleIdList": ["10.3390/vaccines6030063", "30223448"]}, {"Citation": "Wang G.; Narayana J.L.; Mishra B.; Zhang Y.; Wang F.; Wang C.; Zarena D.; Lushnikova T.; Wang X.; Design of antimicrobial peptides: Progress made with human cathelicidin LL-37. Adv Exp Med Biol 2019,1117,215-240", "ArticleIdList": ["10.1007/978-981-13-3588-4_12", "30980360"]}, {"Citation": "Chauhan S.; Dhawan D.K.; Saini A.; Preet S.; Antimicrobial peptides against colorectal cancer-a focused review. Pharmacol Res 2021,167,105529", "ArticleIdList": ["10.1016/j.phrs.2021.105529", "33675962"]}, {"Citation": "Dolkar T.; Trinidad C.M.; Nelson K.C.; Amaria R.N.; Nagarajan P.; Torres-Cabala C.A.; Ivan D.; Prieto V.G.; Tetzlaff M.T.; Curry J.L.; Aung P.P.; Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. J Cutan Pathol 2018,45(7),539-544", "ArticleIdList": ["10.1111/cup.13262", "29665030"]}, {"Citation": "Divyashree M.; Mani M.K.; Reddy D.; Kumavath R.; Ghosh P.; Azevedo V.; Barh D.; Clinical applications of antimicrobial peptides (AMPs):where do we stand now? Protein Pept Lett 2020,27(2),120-134", "ArticleIdList": ["10.2174/0929866526666190925152957", "31553285"]}, {"Citation": "Kim I.; Sanchez K.; McArthur H.L.; Page D.; Immunotherapy in triple-negative breast cancer: Present and future. Curr Breast Cancer Rep 2019,11(4),259-271", "ArticleIdList": ["10.1007/s12609-019-00345-z"]}, {"Citation": "Marra A.; Viale G.; Curigliano G.; Recent advances in triple negative breast cancer: The immunotherapy era. BMC Med 2019,17(1),90", "ArticleIdList": ["10.1186/s12916-019-1326-5", "31068190"]}, {"Citation": "Sambi M.; Bagheri L.; Szewczuk M.R.; Current challenges in cancer immunotherapy: Multimodal approaches to improve efficacy and patient response rates. J Oncol 2019,2019,1-12", "ArticleIdList": ["10.1155/2019/4508794", "30941175"]}, {"Citation": "Reck M.; Rodr\u00edguez-Abreu D.; Robinson A.G.; Hui R.; Cs\u0151szi T.; F\u00fcl\u00f6p A.; Gottfried M.; Peled N.; Tafreshi A.; Cuffe S.; O\u2019Brien M.; Rao S.; Hotta K.; Leiby M.A.; Lubiniecki G.M.; Shentu Y.; Rangwala R.; Brahmer J.R.; Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med 2016,375(19),1823-1833", "ArticleIdList": ["10.1056/NEJMoa1606774", "27718847"]}, {"Citation": "Robert C.; Ribas A.; Hamid O.; Daud A.; Wolchok J.D.; Joshua A.M.; Long G.V.; Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 2015,33,2259-2266", "ArticleIdList": ["29283791"]}, {"Citation": "Robert C.; Long G.V.; Brady B.; Dutriaux C.; Maio M.; Mortier L.; Hassel J.C.; Rutkowski P.; McNeil C.; Kalinka-Warzocha E.; Savage K.J.; Hernberg M.M.; Lebb\u00e9 C.; Charles J.; Mihalcioiu C.; Chiarion-Sileni V.; Mauch C.; Cognetti F.; Arance A.; Schmidt H.; Schadendorf D.; Gogas H.; Lundgren-Eriksson L.; Horak C.; Sharkey B.; Waxman I.M.; Atkinson V.; Ascierto P.A.; Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015,372(4),320-330", "ArticleIdList": ["10.1056/NEJMoa1412082", "25399552"]}, {"Citation": "Herbst R.S.; Soria J.C.; Kowanetz M.; Fine G.D.; Hamid O.; Gordon M.S.; Sosman J.A.; McDermott D.F.; Powderly J.D.; Gettinger S.N.; Kohrt H.E.K.; Horn L.; Lawrence D.P.; Rost S.; Leabman M.; Xiao Y.; Mokatrin A.; Koeppen H.; Hegde P.S.; Mellman I.; Chen D.S.; Hodi F.S.; Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014,515(7528),563-567", "ArticleIdList": ["10.1038/nature14011", "25428504"]}, {"Citation": "Burtness B.; Harrington K.J.; Greil R.; Souli\u00e8res D.; Tahara M.; de Castro G.; Psyrri A.; Bast\u00e9 N.; Neupane P.; Bratland \u00c5.; Fuereder T.; Hughes B.G.M.; Mes\u00eda R.; Ngamphaiboon N.; Rordorf T.; Wan Ishak W.Z.; Hong R.L.; Gonz\u00e1lez Mendoza R.; Roy A.; Zhang Y.; Gumuscu B.; Cheng J.D.; Jin F.; Rischin D.; Lerzo G.; Tatangelo M.; Varela M.; Zarba J.J.; Boyer M.; Gan H.; Gao B.; Hughes B.; Mallesara G.; Rischin D.; Taylor A.; Burian M.; Fuereder T.; Greil R.; Barrios C.H.; de Castro Junior D.O.; Castro G.; Franke F.A.; Girotto G.; Lima I.P.F.; Nicolau U.R.; Pinto G.D.J.; Santos L.; Victorino A-P.; Chua N.; Couture F.; Gregg R.; Hansen A.; Hilton J.; McCarthy J.; Soulieres D.; Ascui R.; Gonzalez P.; Villanueva L.; Torregroza M.; Zambrano A.; Holeckova P.; Kral Z.; Melichar B.; Prausova J.; Vosmik M.; Andersen M.; Gyldenkerne N.; Jurgens H.; Putnik K.; Reinikainen P.; Gruenwald V.; Laban S.; Aravantinos G.; Boukovinas I.; Georgoulias V.; Psyrri A.; Kwong D.; Al-Farhat Y.; Csoszi T.; Erfan J.; Horvai G.; Landherr L.; Remenar E.; Ruzsa A.; Szota J.; Billan S.; Gluck I.; Gutfeld O.; Popovtzer A.; Benasso M.; Bui S.; Ferrari V.; Licitra L.; Nole F.; Fujii T.; Fujimoto Y.; Hanai N.; Hara H.; Matsumoto K.; Mitsugi K.; Monden N.; Nakayama M.; Okami K.; Oridate N.; Shiga K.; Shimizu Y.; Sugasawa M.; Tahara M.; Takahashi M.; Takahashi S.; Tanaka K.; Ueda T.; Yamaguchi H.; Yamazaki T.; Yasumatsu R.; Yokota T.; Yoshizaki T.; Kudaba I.; Stara Z.; Wan Ishak W.Z.; Cheah S.K.; Aguilar Ponce J.; Gonzalez Mendoza R.; Hernandez Hernandez C.; Medina Soto F.; Buter J.; Hoeben A.; Oosting S.; Suijkerbuijk K.; Bratland A.; Brydoey M.; Alvarez R.; Mas L.; Caguioa P.; Querol J.; Regala E.E.; Tamayo M.B.; Villegas E.M.; Kawecki A.; Karpenko A.; Klochikhin A.; Smolin A.; Zarubenkov O.; Goh B.C.; Cohen G.; du Toit J.; Jordaan C.; Landers G.; Ruff P.; Szpak W.; Tabane N.; Brana I.; Iglesias Docampo L.; Lavernia J.; Mesia R.; Abel E.; Muratidu V.; Nielsen N.; Cristina V.; Rordorf T.; Rothschild S.; Hong R-L.; Wang H-M.; Yang M-H.; Yeh S-P.; Yen C-J.; Ngamphaiboon N.; Soparattanapaisarn N.; Sriuranpong V.; Aksoy S.; Cicin I.; Ekenel M.; Harputluoglu H.; Ozyilkan O.; Harrington K.; Agarwala S.; Ali H.; Alter R.; Anderson D.; Bruce J.; Burtness B.; Campbell N.; Conde M.; Deeken J.; Edenfield W.; Feldman L.; Gaughan E.; Goueli B.; Halmos B.; Hegde U.; Hunis B.; Jotte R.; Karnad A.; Khan S.; Laudi N.; Laux D.; Martincic D.; McCune S.; McGaughey D.; Misiukiewicz K.; Mulford D.; Nadler E.; Neupane P.; Nunnink J.; Ohr J.; O\u2019Malley M.; Patson B.; Paul D.; Popa E.; Powell S.; Redman R.; Rella V.; Rocha Lima C.; Sivapiragasam A.; Su Y.; Sukari A.; Wong S.; Yilmaz E.; Yorio J.; Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019,394(10212),1915-1928", "ArticleIdList": ["10.1016/S0140-6736(19)32591-7", "31679945"]}, {"Citation": "Paz-Ares L.; Luft A.; Vicente D.; Tafreshi A.; G\u00fcm\u00fc\u015f M.; Mazi\u00e8res J.; Hermes B.; \u00c7ay \u015eenler F.; Cs\u0151szi T.; F\u00fcl\u00f6p A.; Rodr\u00edguez-Cid J.; Wilson J.; Sugawara S.; Kato T.; Lee K.H.; Cheng Y.; Novello S.; Halmos B.; Li X.; Lubiniecki G.M.; Piperdi B.; Kowalski D.M.; Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018,379(21),2040-2051", "ArticleIdList": ["10.1056/NEJMoa1810865", "30280635"]}, {"Citation": "Vanneman M.; Dranoff G.; Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012,12(4),237-251", "ArticleIdList": ["10.1038/nrc3237", "22437869"]}, {"Citation": "Hughes P.E.; Caenepeel S.; Wu L.C.; Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol 2016,37(7),462-476", "ArticleIdList": ["10.1016/j.it.2016.04.010", "27216414"]}, {"Citation": "Grosser R.; Cherkassky L.; Chintala N.; Adusumilli P.S.; Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 2019,36(5),471-482", "ArticleIdList": ["10.1016/j.ccell.2019.09.006", "31715131"]}, {"Citation": "Chiossone L.; Dumas P.Y.; Vienne M.; Vivier E.; Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol 2018,18(11),671-688", "ArticleIdList": ["10.1038/s41577-018-0061-z", "30209347"]}, {"Citation": "Al Zein M.; Boukhdoud M.; Shammaa H.; Mouslem H.; El Ayoubi L.M.; Iratni R.; Issa K.; Khachab M.; Assi H.I.; Sahebkar A.; Eid A.H.; Immunotherapy and immunoevasion of colorectal cancer. Drug Discov Today 2023,28(9),103669", "ArticleIdList": ["10.1016/j.drudis.2023.103669", "37328052"]}, {"Citation": "Roy D.; Gilmour C.; Patnaik S.; Wang L.L.; Combinatorial blockade for cancer immunotherapy: Targeting emerging immune checkpoint receptors. Front Immunol 2023,14,1264327", "ArticleIdList": ["10.3389/fimmu.2023.1264327", "37928556"]}, {"Citation": "Anyaegbu C.C.; Lake R.A.; Heel K.; Robinson B.W.; Fisher S.A.; Chemotherapy enhances cross-presentation of nuclear tumor antigens. PLoS One 2014,9(9),e107894", "ArticleIdList": ["10.1371/journal.pone.0107894", "25243472"]}, {"Citation": "Arora R.; Malhotra P.; Chawla R.; Gupta D.; Sharma R.K.; IndHerbMed Can Ther Prev. Available from : https://www.sciencedirect.com/journal/journal-of-herbal-medicine 2010"}, {"Citation": "Borse S.P.; Singh D.P.; Nivsarkar M.; Understanding the relevance of herb\u2013drug interaction studies with special focus on interplays: A prerequisite for integrative medicine. Porto Biomed J 2019,4(2),e15", "ArticleIdList": ["10.1016/j.pbj.0000000000000015", "31595257"]}, {"Citation": "Gorzynik-Debicka M.; Przychodzen P.; Cappello F.; Kuban-Jankowska A.; Marino Gammazza A.; Knap N.; Wozniak M.; Gorska-Ponikowska M.; Potential health benefits of olive oil and plant polyphenols. Int J Mol Sci 2018,19(3),686", "ArticleIdList": ["10.3390/ijms19030686", "29495598"]}, {"Citation": "Kris-Etherton P.M.; Hecker K.D.; Bonanome A.; Coval S.M.; Binkoski A.E.; Hilpert K.F.; Griel A.E.; Etherton T.D.; Bioactive compounds in foods: Their role in the prevention of cardiovascular disease and cancer. Am J Med 2002,113(9),71-88", "ArticleIdList": ["10.1016/S0002-9343(01)00995-0", "12566142"]}, {"Citation": "Banyal A.; Tiwari S.; Sharma A.; Chanana I.; Patel S.K.; Kulshrestha S.; Kumar P.; Vinca alkaloids as a potential cancer therapeutics: Recent update and future challenges. Biotech 2023,13,1-7"}, {"Citation": "Wang C.; Aguilar A.; Ojima I.; Strategies for the drug discovery and development of taxane anticancer therapeutics. Expert Opin Drug Discov 2022,17(11),1193-1207", "ArticleIdList": ["10.1080/17460441.2022.2131766", "36200759"]}, {"Citation": "Buzun K.; Bielawska A.; Bielawski K.; Gornowicz A.; DNA topoisomerases as molecular targets for anticancer drugs. J Enzyme Inhib Med Chem 2020,35(1),1781-1799", "ArticleIdList": ["10.1080/14756366.2020.1821676", "32975138"]}, {"Citation": "Motyka S.; Jafernik K.; Ekiert H.; Sharifi-Rad J.; Calina D.; Al-Omari B.; Szopa A.; Cho W.C.; Podophyllotoxin and its derivatives: Potential anticancer agents of natural origin in cancer chemotherapy. Biomed Pharmacother 2023,158,114145", "ArticleIdList": ["10.1016/j.biopha.2022.114145", "36586242"]}, {"Citation": "Kikuyama F.; Suzuki S.; Jibiki A.; Yokoyama Y.; Kawazoe H.; Kitanaka S.; Nakamura T.; Ingenol mebutate inhibits the growth of pancreatic cancer cells in vitro via STING with an efficacy comparable to that of clinically used anticancer agents. J Nat Med 2023,77(2),343-351", "ArticleIdList": ["10.1007/s11418-023-01682-1", "36694038"]}, {"Citation": "Du G.H.; Wang Z.; Li L.; Du GH.; Homoharringtonine. Nat Smal Mol Drug Plant 2018,521-527"}, {"Citation": "Hura N.; Sawant A.V.; Kumari A.; Guchhait S.K.; Panda D.; Combretastatin-inspired heterocycles as antitubulin anticancer agents. ACS Omega 2018,3(8),9754-9769", "ArticleIdList": ["10.1021/acsomega.8b00996", "31459105"]}, {"Citation": "Alsamri H.; El Hasasna H.; Al Dhaheri Y.; Eid A.H.; Attoub S.; Iratni R.; Carnosol, a natural polyphenol, inhibits migration, metastasis, and tumor growth of breast cancer via a ROS-dependent proteasome degradation of STAT3. Front Oncol 2019,9,743", "ArticleIdList": ["10.3389/fonc.2019.00743", "31456939"]}, {"Citation": "Alsamri H.; Hasasna H.E.; Baby B.; Alneyadi A.; Dhaheri Y.A.; Ayoub M.A.; Eid A.H.; Vijayan R.; Iratni R.; Carnosol is a novel inhibitor of p300 acetyltransferase in breast cancer. Front Oncol 2021,11,664403", "ArticleIdList": ["10.3389/fonc.2021.664403", "34055630"]}, {"Citation": "Alsamri H.; Alneyadi A.; Muhammad K.; Ayoub M.A.; Eid A.; Iratni R.; Carnosol induces p38-mediated ER stress response and autophagy in human breast cancer cells. Front Oncol 2022,12,911615", "ArticleIdList": ["10.3389/fonc.2022.911615", "35712465"]}, {"Citation": "Kou X.; Wang X.; Ji R.; Liu L.; Qiao Y.; Lou Z.; Ma C.; Li S.; Wang H.; Ho C.T.; Occurrence, biological activity and metabolism of 6-shogaol. Food Funct 2018,9(3),1310-1327", "ArticleIdList": ["10.1039/C7FO01354J", "29417118"]}, {"Citation": "Catanzaro E.; Canistro D.; Pellicioni V.; Vivarelli F.; Fimognari C.; Anticancer potential of allicin: A review. Pharmacol Res 2022,177,106118", "ArticleIdList": ["10.1016/j.phrs.2022.106118", "35134476"]}, {"Citation": "Alos H.C.; Billones J.B.; Castillo A.L.; Vasquez R.D.; Alpinumisoflavone against cancer pro-angiogenic targets: in silico, in vitro, and In ovo evaluation. Daru 2022,30(2),273-288", "ArticleIdList": ["10.1007/s40199-022-00445-9", "35925539"]}, {"Citation": "Malik Z.; Parveen R.; Parveen B.; Zahiruddin S.; Aasif Khan M.; Khan A.; Massey S.; Ahmad S.; Husain S.A.; Anticancer potential of andrographolide from Andrographis paniculata (Burm.f.) Nees and its mechanisms of action. J Ethnopharmacol 2021,272,113936", "ArticleIdList": ["10.1016/j.jep.2021.113936", "33610710"]}, {"Citation": "Imran M.; Aslam Gondal T.; Atif M.; Shahbaz M.; Batool Qaisarani T.; Hanif Mughal M.; Salehi B.; Martorell M.; Sharifi-Rad J.; Apigenin as an anticancer agent. Phytother Res 2020,34(8),1812-1828", "ArticleIdList": ["10.1002/ptr.6647", "32059077"]}, {"Citation": "Ke M.; Zhang Z.; Xu B.; Zhao S.; Ding Y.; Wu X.; Wu R.; Lv Y.; Dong J.; Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. Int Immunopharmacol 2019,75,105824", "ArticleIdList": ["10.1016/j.intimp.2019.105824", "31437792"]}, {"Citation": "Slika H.; Mansour H.; Wehbe N.; Nasser S.A.; Iratni R.; Nasrallah G.; Shaito A.; Ghaddar T.; Kobeissy F.; Eid A.H.; Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms. Biomed Pharmacother 2022,146,112442", "ArticleIdList": ["10.1016/j.biopha.2021.112442", "35062053"]}, {"Citation": "Tomeh M.; Hadianamrei R.; Zhao X.; A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci 2019,20(5),1033", "ArticleIdList": ["10.3390/ijms20051033", "30818786"]}, {"Citation": "Oh S.T.; Lee S.; Hua C.; Koo B.S.; Pak S.C.; Kim D.I.; Jeon S.; Shin B.A.; Decursin induces apoptosis in glioblastoma cells, but not in glial cells via a mitochondria-related caspase pathway. Korean J Physiol Pharmacol 2019,23(1),29-35", "ArticleIdList": ["10.4196/kjpp.2019.23.1.29", "30627007"]}, {"Citation": "Zhang W.; Su J.; Xu H.; Yu S.; Liu Y.; Zhang Y.; Sun L.; Yue Y.; Zhou X.; Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells. PLoS One 2017,12(6),e0179672", "ArticleIdList": ["10.1371/journal.pone.0179672", "28617852"]}, {"Citation": "Gan R.Y.; Li H.B.; Sui Z.Q.; Corke H.; Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review. Crit Rev Food Sci Nutr 2018,58(6),924-941", "ArticleIdList": ["10.1080/10408398.2016.1231168", "27645804"]}, {"Citation": "Akkol E.K.; Tatl\u0131 I.I.; Karatoprak G.\u015e.; A\u011far O.T.; Y\u00fccel \u00c7.; Sobarzo-S\u00e1nchez E.; Capasso R.; Is emodin with anticancer effects completely innocent? Two sides of the coin. Cancers 2021,13(11),2733", "ArticleIdList": ["10.3390/cancers13112733", "34073059"]}, {"Citation": "Hsiao Y.C.; Peng S.F.; Lai K.C.; Liao C.L.; Huang Y.P.; Lin C.C.; Lin M.L.; Liu K.C.; Tsai C.C.; Ma Y.S.; Chung J.G.; Genistein induces apoptosis in vitro and has antitumor activity against human leukemia HL-60 cancer cell xenograft growth in vivo. Environ Toxicol 2019,34(4),443-456", "ArticleIdList": ["10.1002/tox.22698", "30618158"]}, {"Citation": "Joo J.H.; Hong, S.S.; Cho, Y.R.; Seo, D.W.; 10-Gingerol inhibits proliferation and invasion of MDA-MB-231 breast cancer cells through suppression of Akt and p38MAPK activity. Oncol Rep 2016,35,779-84", "ArticleIdList": ["10.1002/ptr.6134", "30009484"]}, {"Citation": "Zhang Z.; Yang L.; Hou J.; Tian S.; Liu Y.; Molecular mechanisms underlying the anticancer activities of licorice flavonoids. J Ethnopharmacol 2021,267,113635", "ArticleIdList": ["10.1016/j.jep.2020.113635", "33246112"]}, {"Citation": "Liu K.; Zhao F.; Yan J.; Xia Z.; Jiang D.; Ma P.; Hispidulin: A promising flavonoid with diverse anti-cancer properties. Life Sci 2020,259,118395", "ArticleIdList": ["10.1016/j.lfs.2020.118395", "32905830"]}, {"Citation": "Kim J.S.; Jeong S.K.; Oh S.J.; Lee C.G.; Kang Y.R.; Jo W.S.; Jeong M.H.; The resveratrol analogue, HS\u20111793, enhances the effects of radiation therapy through the induction of anti-tumor immunity in mammary tumor growth. Int J Oncol 2020,56(6),1405-1416", "ArticleIdList": ["10.3892/ijo.2020.5017", "32236622"]}, {"Citation": "Deng N.; Qiao M.; Li Y.; Liang F.; Li J.; Liu Y.; Anticancer effects of licochalcones: A review of the mechanisms. Front Pharmacol 2023,14,1074506", "ArticleIdList": ["10.3389/fphar.2023.1074506", "36755942"]}, {"Citation": "Nagini S.; Nivetha R.; Palrasu M.; Mishra R.; Nimbolide, a neem limonoid, is a promising candidate for the anticancer drug arsenal. J Med Chem 2021,64(7),3560-3577", "ArticleIdList": ["10.1021/acs.jmedchem.0c02239", "33739088"]}, {"Citation": "Xu J.; Wu Y.; Lu G.; Xie S.; Ma Z.; Chen Z.; Shen H.M.; Xia D.; Importance of ROS-mediated autophagy in determining apoptotic cell death induced by physapubescin B. Redox Biol 2017,12,198-207", "ArticleIdList": ["10.1016/j.redox.2017.02.017", "28258023"]}, {"Citation": "Lin W.S.; Leland J.V.; Ho C.T.; Pan M.H.; Occurrence, bioavailability, anti-inflammatory, and anticancer effects of pterostilbene. J Agric Food Chem 2020,68(46),12788-12799", "ArticleIdList": ["10.1021/acs.jafc.9b07860", "32064876"]}, {"Citation": "Varoni E.M.; Lo Faro A.F.; Sharifi-Rad J.; Iriti M.; Anticancer molecular mechanisms of resveratrol. Front Nutr 2016,3,8", "ArticleIdList": ["10.3389/fnut.2016.00008", "27148534"]}, {"Citation": "Su X.; Jiang X.; Meng L.; Dong X.; Shen Y.; Xin Y.; Anticancer activity of sulforaphane: The epigenetic mechanisms and the Nrf2 signaling pathway. Oxid Med Cell Longev 2018,2018,1-10", "ArticleIdList": ["10.1155/2018/5438179", "29977456"]}, {"Citation": "Islam M.T.; Khalipha A.B.R.; Bagchi R.; Mondal M.; Smrity S.Z.; Uddin S.J.; Shilpi J.A.; Rouf R.; Anticancer activity of thymol: A literature-based review and docking study with Emphasis on its anticancer mechanisms. IUBMB Life 2019,71(1),9-19", "ArticleIdList": ["10.1002/iub.1935", "30308112"]}, {"Citation": "Asaduzzaman Khan M.; Tania M.; Fu S.; Fu J.; Thymoquinone, as an anticancer molecule: From basic research to clinical investigation. Oncotarget 2017,8(31),51907-51919", "ArticleIdList": ["10.18632/oncotarget.17206", "28881699"]}, {"Citation": "Yin R.; Li T.; Tian J.X.; Xi P.; Liu R.H.; Ursolic acid, a potential anticancer compound for breast cancer therapy. Crit Rev Food Sci Nutr 2018,58(4),568-574", "ArticleIdList": ["10.1080/10408398.2016.1203755", "27469428"]}, {"Citation": "Atteeq M.; Evaluating anticancer properties of Withaferin A\u2014a potent phytochemical. Front Pharmacol 2022,13,975320", "ArticleIdList": ["10.3389/fphar.2022.975320", "36339589"]}, {"Citation": "Zoi V.; Galani V.; Lianos G.D.; Voulgaris S.; Kyritsis A.P.; Alexiou G.A.; The role of curcumin in cancer treatment. Biomedicines 2021,9(9),1086", "ArticleIdList": ["10.3390/biomedicines9091086", "34572272"]}, {"Citation": "Wang Y.; Lai H.; Fan X.; Luo L.; Duan F.; Jiang Z.; Wang Q.; Leung E.L.H.; Liu L.; Yao X.; Gossypol inhibits non-small cell lung cancer cells proliferation by targeting EGFRL858R/T790M. Front Pharmacol 2018,9,728", "ArticleIdList": ["10.3389/fphar.2018.00728", "30038571"]}, {"Citation": "Sohel M.; Biswas P.; Al Amin M.; Hossain M.A.; Sultana H.; Dey D.; Aktar S.; Setu A.; Khan M.S.; Paul P.; Islam M.N.; Rahman M.A.; Kim B.; Al Mamun A.; Genistein, a potential phytochemical against breast cancer treatment-insight into the molecular mechanisms. Processes 2022,10(2),415", "ArticleIdList": ["10.3390/pr10020415"]}, {"Citation": "Liu Q.; Hodge J.; Wang J.; Wang Y.; Wang L.; Singh U.P.; Li Y.; Yao Y.; Wang D.; Ai W.; Nagarkatti P.; Chen H.; Xu P.; Murphy E.A.; Fan D.; Emodin reduces breast cancer lung metastasis by suppressing macrophage-induced breast cancer cell epithelial-mesenchymal transition and cancer stem cell formation. Theranostics 2020,10(18),8365-8381", "ArticleIdList": ["10.7150/thno.45395", "32724475"]}, {"Citation": "Giuli M.V.; Hanieh P.N.; Giuliani E.; Rinaldi F.; Marianecci C.; Screpanti I.; Checquolo S.; Carafa M.; Current trends in ATRA delivery for cancer therapy. Pharmaceutics 2020,12(8),707", "ArticleIdList": ["10.3390/pharmaceutics12080707", "32731612"]}, {"Citation": "Chow S.; Berek J.S.; Dorigo O.; Development of therapeutic vaccines for ovarian cancer. Vaccines 2020,8(4),657", "ArticleIdList": ["10.3390/vaccines8040657", "33167428"]}, {"Citation": "Paul S.; Roy D.; Pati S.; Sa G.; The adroitness of andrographolide as a natural weapon against colorectal cancer. Front Pharmacol 2021,12,731492", "ArticleIdList": ["10.3389/fphar.2021.731492", "34795581"]}, {"Citation": "Wu K.; Yang Q.; Mu Y.; Zhou L.; Liu Y.; Zhou Q.; He B.; Berberine inhibits the proliferation of colon cancer cells by inactivating Wnt/\u03b2-catenin signaling. Int J Oncol 2012,41(1),292-298", "ArticleIdList": ["22469784"]}, {"Citation": "Baster Z.; Li L.; Kukkurainen S.; Chen J.; Pentik\u00e4inen O.; Gy\u0151rffy B.; Hyt\u00f6nen V.P.; Zhu H.; Rajfur Z.; Huang C.; Cyanidin-3-glucoside binds to talin and modulates colon cancer cell adhesions and 3D growth. FASEB J 2020,34(2),2227-2237", "ArticleIdList": ["10.1096/fj.201900945R", "31916632"]}, {"Citation": "Ni X.; Shang F.S.; Wang T.F.; Wu D.J.; Chen D.G.; Zhuang B.; Ellagic acid induces apoptosis and autophagy in colon cancer through the AMPK/mTOR pathway. Tissue Cell 2023,81,102032", "ArticleIdList": ["10.1016/j.tice.2023.102032", "36701898"]}, {"Citation": "Wang Y.; Yuan A.J.; Wu Y.J.; Wu L.M.; Zhang L.; Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations. J Funct Foods 2023,100,105384", "ArticleIdList": ["10.1016/j.jff.2022.105384"]}, {"Citation": "Xue N.; Zhou Q.; Ji M.; Jin J.; Lai F.; Chen J.; Zhang M.; Jia J.; Yang H.; Zhang J.; Li W.; Jiang J.; Chen X.; Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. Sci Rep 2017,7(1),39011", "ArticleIdList": ["10.1038/srep39011", "28045028"]}, {"Citation": "Chen T.; da Fonseca C.; Sch\u00f6nthal A.; Intranasal perillyl alcohol for glioma therapy: molecular mechanisms and clinical development. Int J Mol Sci 2018,19(12),3905", "ArticleIdList": ["10.3390/ijms19123905", "30563210"]}, {"Citation": "Ng Q.S.; Mandeville H.; Goh V.; Alonzi R.; Milner J.; Carnell D.; Meer K.; Padhani A.R.; Saunders M.I.; Hoskin P.J.; Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 2012,23(1),231-237", "ArticleIdList": ["10.1093/annonc/mdr332", "21765046"]}, {"Citation": "Starska-Kowarska K.; Dietary carotenoids in head and neck cancer\u2014molecular and clinical implications. Nutrients 2022,14(3),531", "ArticleIdList": ["10.3390/nu14030531", "35276890"]}, {"Citation": "Zhang S.; Wang D.; Huang J.; Hu Y.; Xu Y.; Application of capsaicin as a potential new therapeutic drug in human cancers. J Clin Pharm Ther 2020,45(1),16-28", "ArticleIdList": ["10.1111/jcpt.13039", "31545523"]}, {"Citation": "Koltai T.; Fliegel L.; Role of silymarin in cancer treatment: Facts, hypotheses, and questions. J Evid Based Integr Med 2022,27", "ArticleIdList": ["10.1177/2515690X211068826"]}, {"Citation": "Mirahmadi M.; Azimi-Hashemi S.; Saburi E.; Kamali H.; Pishbin M.; Hadizadeh F.; Potential inhibitory effect of lycopene on prostate cancer. Biomed Pharmacother 2020,129,110459", "ArticleIdList": ["10.1016/j.biopha.2020.110459", "32768949"]}, {"Citation": "Carastro L.; Vallebuona E.; Cordova R.; Gannon A.; Kim S.; Costello C.; Declet-Bauzo R.; Kumar N.; Park J.; Polyphenon E.; Polyphenon E effects on gene expression in PC-3 prostate cancer cells. Int J Mol Sci 2022,23(22),14328", "ArticleIdList": ["10.3390/ijms232214328", "36430806"]}, {"Citation": "Fern\u00e1ndez-L\u00e1zaro D.; Mielgo-Ayuso J.; C\u00f3rdova Mart\u00ednez A.; Seco-Calvo J.; Iron and physical activity: Bioavailability enhancers, properties of black pepper (bioperine) and potential applications. Nutrients 2020,12(6),1886", "ArticleIdList": ["10.3390/nu12061886", "32599787"]}, {"Citation": "Berkow R.L.; Schlabach L.; Dodson R.; Benjamin W.H.; Pettit G.R.; Rustagi P.; Kraft A.S.; in vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res 1993,53(12),2810-2815", "ArticleIdList": ["8504423"]}, {"Citation": "Velmurugan B.K.; Lin J.T.; Mahalakshmi B.; Chuang Y.C.; Lin C.C.; Lo Y.S.; Hsieh M.J.; Chen M.K.; Luteolin-7-O-glucoside inhibits oral cancer cell migration and invasion by regulating matrix metalloproteinase-2 expression and extracellular signal-regulated kinase pathway. Biomolecules 2020,10(4),502", "ArticleIdList": ["10.3390/biom10040502", "32224968"]}, {"Citation": "Roshani M.; Jafari A.; Loghman A.; Sheida A.H.; Taghavi T.; Tamehri Zadeh S.S.; Hamblin M.R.; Homayounfal M.; Mirzaei H.; Applications of resveratrol in the treatment of gastrointestinal cancer. Biomed Pharmacother 2022,153,113274", "ArticleIdList": ["10.1016/j.biopha.2022.113274", "35724505"]}, {"Citation": "Iwasa S.; Morizane C.; Okusaka T.; Ueno H.; Ikeda M.; Kondo S.; Tanaka T.; Nakachi K.; Mitsunaga S.; Kojima Y.; Hagihara A.; Hiraoka N.; Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol 2010,40(4),313-318", "ArticleIdList": ["10.1093/jjco/hyp173", "20047862"]}, {"Citation": "Yuan H.; Ma Q.; Ye L.; Piao G.; The traditional medicine and modern medicine from natural products. Molecules 2016,21(5),559", "ArticleIdList": ["10.3390/molecules21050559", "27136524"]}, {"Citation": "Manach C.; Scalbert A.; Morand C.; R\u00e9m\u00e9sy C.; Jim\u00e9nez L.; Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004,79(5),727-747", "ArticleIdList": ["10.1093/ajcn/79.5.727", "15113710"]}, {"Citation": "Anand P.; Kunnumakkara A.B.; Newman R.A.; Aggarwal B.B.; Bioavailability of curcumin: Problems and promises. Mol Pharm 2007,4(6),807-818", "ArticleIdList": ["10.1021/mp700113r", "17999464"]}, {"Citation": "Wenzel E.; Somoza V.; Metabolism and bioavailability oftrans-resveratrol. Mol Nutr Food Res 2005,49(5),472-481", "ArticleIdList": ["10.1002/mnfr.200500010", "15779070"]}, {"Citation": "Shen L.; Ji H.F.; Jiang D.M.; Li J.; Nanoparticle formulations enhance the bioavailability of resveratrol: An in-vitro assessment. J Pharm Pharmacol 2012,64,889-897"}, {"Citation": "Naeem A.; Hu P.; Yang M.; Zhang J.; Liu Y.; Zhu W.; Zheng Q.; Natural products as anticancer agents: Current status and future perspectives. Molecules 2022,27(23),8367", "ArticleIdList": ["10.3390/molecules27238367", "36500466"]}, {"Citation": "Cragg G.M.; Newman D.J.; Natural products: A continuing source of novel drug leads. Biochim Biophys Acta, Gen Subj 2013,1830(6),3670-3695", "ArticleIdList": ["10.1016/j.bbagen.2013.02.008", "23428572"]}]}], "History": [{"Year": "2023", "Month": "9", "Day": "15"}, {"Year": "2023", "Month": "11", "Day": "27"}, {"Year": "2023", "Month": "12", "Day": "5"}, {"Year": "2024", "Month": "7", "Day": "15", "Hour": "6", "Minute": "42"}, {"Year": "2024", "Month": "1", "Day": "27", "Hour": "12", "Minute": "43"}, {"Year": "2024", "Month": "1", "Day": "27", "Hour": "5", "Minute": "29"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38279745", "10.2174/0115680266282518231231075311", "CTMC-EPUB-137903"]}}]}